The discovery of JAK2 mutations allowed the development of JAK2 inhibitors for target therapies, including ruxolitinib, approved for patients with primary or secondary myelofibrosis and hydroxyurea‐resistant or intolerant PV patients. The gene discussed is JAK2; the disease is acquired polycythemia vera.